, Tracking Stock Market Picks
Enter Symbol:
Arqule, Inc. (ARQL) [hlAlert]

down 44.47 %

Arqule, Inc. (ARQL) rated Outperform with price target $6 by Oppenheimer

Posted on: Monday,  Dec 1, 2008  9:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Arqule, Inc. (NASDAQ: ARQL) on 12/01/2008, when the stock price was $3.17. Since
then, Arqule, Inc. has lost 44.48% as of 01/22/2016's recent price of $1.76.
If you would have followed this Oppenheimer's recommendation on ARQL, you would have lost 44.47% of your investment in 2608 days.

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/1/2008 9:25 AM Buy
3.17 6.00
as of 12/24/2008
1 Week down  -8.22 %
1 Month down  -2.13 %
3 Months   
1 YTD down  -2.13 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy